Orthofix Medical Inc. (NASDAQ:OFIX) Receives Average Rating of “Moderate Buy” from Brokerages

Orthofix Medical Inc. (NASDAQ:OFIX) has received a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.33.

A number of research firms recently weighed in on OFIX. Roth Mkm restated a “buy” rating and issued a $22.00 price target (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Stifel Nicolaus raised Orthofix Medical from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $24.00 in a report on Friday, November 8th. Finally, Canaccord Genuity Group began coverage on Orthofix Medical in a report on Wednesday, January 22nd. They set a “buy” rating and a $24.00 price objective for the company.

Insider Activity at Orthofix Medical

In related news, CFO Julie Andrews sold 4,655 shares of the company’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the completion of the transaction, the chief financial officer now directly owns 28,312 shares in the company, valued at approximately $506,501.68. This represents a 14.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Massimo Calafiore sold 10,078 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $16.83, for a total value of $169,612.74. Following the completion of the transaction, the chief executive officer now owns 133,354 shares of the company’s stock, valued at $2,244,347.82. The trade was a 7.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,675 shares of company stock worth $423,238. 2.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Orthofix Medical

A number of institutional investors have recently added to or reduced their stakes in OFIX. American Century Companies Inc. grew its position in Orthofix Medical by 15.7% during the second quarter. American Century Companies Inc. now owns 54,964 shares of the medical device company’s stock valued at $729,000 after acquiring an additional 7,475 shares during the period. XTX Topco Ltd purchased a new stake in Orthofix Medical during the second quarter valued at about $175,000. Sei Investments Co. grew its position in Orthofix Medical by 24.6% during the second quarter. Sei Investments Co. now owns 46,195 shares of the medical device company’s stock valued at $613,000 after acquiring an additional 9,114 shares during the period. Gabelli Funds LLC grew its position in Orthofix Medical by 7.9% during the second quarter. Gabelli Funds LLC now owns 157,500 shares of the medical device company’s stock valued at $2,088,000 after acquiring an additional 11,500 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its position in Orthofix Medical by 31.3% during the second quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company’s stock valued at $33,894,000 after acquiring an additional 609,137 shares during the period. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Stock Up 1.2 %

Orthofix Medical stock opened at $18.59 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.39 and a quick ratio of 1.11. Orthofix Medical has a 1-year low of $12.08 and a 1-year high of $20.73. The company has a market cap of $710.32 million, a PE ratio of -5.94 and a beta of 1.10. The stock’s 50 day moving average price is $18.08 and its 200 day moving average price is $17.03.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings results on Thursday, November 7th. The medical device company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.57). Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. The business had revenue of $196.61 million during the quarter, compared to analysts’ expectations of $196.60 million. During the same quarter last year, the firm earned ($0.77) earnings per share. On average, sell-side analysts predict that Orthofix Medical will post -2.81 EPS for the current fiscal year.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.